Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR NORO RANDRIANJAFINIMANANA
63 RUE NOLLET, 75017 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
Journal of orthopaedic surgery and research · 2025
Current oncology (Toronto, Ont.) · 2025
Hereditary predisposition substantially shapes prevention and management across urologic oncology. This narrative review synthesizes contemporary, practice-oriented guidance on whom to test, what to test, how to act on results, and how to implement care equitably for hereditary forms of prostate cancer, renal cell carcinoma (RCC), urothelial carcinoma, pheochromocytoma/paraganglioma (PPGL), and adrenocortical carcinoma (ACC). We delineate between forms of indication-driven germline testing (e.g., universal testing in metastatic prostate cancer; early-onset, bilateral/multifocal, or syndromic RCC; reflex tumor mismatch repair (MMR)/microsatellite instability (MSI) screening in upper-tract urothelial carcinoma (UTUC); universal testing in PPGL; universal TP53 testing in ACC) and pair these strategies with minimum actionable gene sets and syndrome-specific surveillance frameworks. Key points include targeted prostate-specific antigen screening in BRCA2 carriers and the impact of BRCA/ATM variants on reclassification during active surveillance; major hereditary RCC syndromes with genotype-tailored surveillance and pathway-directed therapy (e.g., HIF-2α inhibition for von Hippel–Lindau disease); UTUC/bladder cancer in Lynch syndrome with tumor MMR/MSI screening, annual urinalysis (selective cytology), and immunotherapy opportunities in deficient MMR disease/MSI-H; PPGL management emphasizing universal germline testing, intensified surveillance for SDHB, cortical-sparing adrenalectomy, and emerging HIF-2α inhibition; and ACC care modified by Li–Fraumeni syndrome (minimization of radiation/genotoxic therapy with whole-body imaging surveillance). Testicular germ cell tumor remains largely polygenic, with no routine germline testing in typical presentations. Finally, we provide pre-/post-test genetic-counseling checklists and mainstreamed workflows with equity metrics to operationalize precision care and close real-world access gaps.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of clinical medicine · 2026 · Journal Article
Kurishima H, Tomata Y, Yamada N, Noro A, et al.
Gan to kagaku ryoho. Cancer & chemotherapy · 2026 · Journal Article
Noro H, Sasaki T, Takeda Y, Matsuyama T, et al.
Surgical neurology international · 2025 · Case Reports
Ito S, Ichikawa N, Miyazaki T, Noro A, et al.
Journal of personalized medicine · 2025 · Journal Article
Sugizaki Y, Utsumi T, Ikeda R, Ishitsuka N, et al.
International journal of urology : official journal of the Japanese Urological Association · 2025 · Journal Article
Somoto T, Utsumi T, Ishitsuka N, Noro T, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Journal Article
Campos-Segura AV, Alvarez K, Murillo Carrasco AG, Rossi BM, et al.
Nanoscale advances · 2025 · Journal Article
N V, Sekaran S, Suresh Babu R, Sudhakar S, et al.
Acta neurochirurgica · 2025 · Journal Article
Amano Y, Asayama B, Noro S, Abe T, et al.
Cancers · 2025 · Journal Article
Kamiya N, Noro T, Okazaki T, Ishitsuka N, et al.
Cancers · 2026 · Journal Article
Noro T, Utsumi T, Ikeda R, Ishitsuka N, et al.
Revista gaucha de enfermagem · 2025 · Journal Article
Moraes MADC, Assis MCS, Acosta AM, Fernandes APW, et al.
International journal of clinical oncology · 2025 · Journal Article
Yoneyama F, Fujita N, Kawashima Y, Shinohara M, et al.
Journal of orthopaedic surgery and research · 2025 · Journal Article
Kurishima H, Yamada N, Noro A, Tanaka H, et al.
Acta odontologica Scandinavica · 2026 · Journal Article
Noro A, Snäll J, Ventä I
Revista gaucha de enfermagem · 2025 · Journal Article
Moraes MADC, Assis MCS, Acosta AM, Fernandes APW, et al.
Journal of occupational health · 2025 · Journal Article
Tani N, Takao Y, Noro S, Sakai K, et al.
Frontiers in sports and active living · 2024 · Journal Article
Hata K, Yanagiya T, Noro H, Suzuki Y
Neurosurgery practice · 2025 · Case Reports
Noro S, Asayama B, Saiki S, Amano Y, et al.
Neurology · 2026 · Journal Article
Noro S, Hatayama T, Iwai Y, Toda H, et al.
Current oncology (Toronto, Ont.) · 2025 · Journal Article
Somoto T, Utsumi T, Ikeda R, Ishitsuka N, et al.
The Journal of the Association of Physicians of India · 2025 · Journal Article
Rao VK, N T, Rs M
Archives of osteoporosis · 2025 · Journal Article
N BV, A MS, A DR, H SG, et al.
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland · 2025 · Journal Article
Iwanaga N, Sugo H, Yamamoto T, Noro T, et al.
Ciencia & saude coletiva · 2025 · English Abstract
Ferreira TPDS, Noro LRA
Cureus · 2026 · Case Reports
R S, Nanda M S, Adalarasan S, Subramanian Y, et al.